Abstract
The editorial discusses the beneficial effects of sodium-glucose cotransporter-2 (SGLT-2)inhibitors inpatients with diabetic nephropathyand their underutilization in government hospitals in India for the treatment of diabetic nephropathy.The authors provide a comprehensive analysis of various factors contributing to the under-prescription of these medications, includinglack of awareness and education among healthcare professionals, limited availability and accessibility of medications, high cost, and poor adherence to evidence-based guidelines. Addressing these factors through education, research, and affordable pricing and reimbursement policies may help improve the appropriate prescription of SGLT-2 inhibitors in government hospitals in India.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
